论文部分内容阅读
CyprowPharmaceutical公司的CPC－111（1，6-二磷酸果糖，fructose1，6-diphosphate）在心力衰竭和镰形血细胞贫血症的Ⅱ期临床中显示，能增强左心室（LV）功能受损病人的心泵功能。在这一研究中，47例接受诊断性心导管插入术的病人静脉输注CPC－11170～150mg／kg。病人经确诊
Cyprow Pharmaceutical’s CPC-111 (fructose 1, 6-diphosphate) has shown to increase the heart of patients with impaired left ventricular (LV) function in phase II clinical trials of heart failure and sickle cell anemia Pump function. In this study, 47 patients undergoing diagnostic cardiac catheterization received intravenous infusion of CPC-11170-150 mg / kg. The patient is diagnosed